The University of Southampton
University of Southampton Institutional Repository

Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013-2021: a retrospective cohort study

Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013-2021: a retrospective cohort study
Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013-2021: a retrospective cohort study

Objectives: to examine patterns in the dispensing of category X medications (Therapeutic Goods Administration categorisation system for prescribing medicines in pregnancy) to women aged 15-49 years in Australia during 2008-2021, and patterns of concurrent use of hormonal long-acting reversible contraception (LARC) and other hormonal contraception.

Study design: retrospective cohort study; analysis of 10% random sample of national Pharmaceutical Benefits Scheme dispensing data.

Participants, Setting: women aged 15-49 years dispensed category X medications, Australia, 1 January 2013 - 31 December 2021.

Main outcome measures: incident and prevalent dispensing of category X medications, by medication class, age group, and year; contraceptive overlap (proportions of women dispensed hormonal LARC or other hormonal contraception that overlapped the first dispensing of category X medications), by medication class.

Results: among 15 627 women aged 15-49 years dispensed category X medications during 2013-2021, the prevalence of dispensing increased from 4.6 in 2013 to 8.7 per 1000 women aged 15-49 years in 2021; the largest increase was for the dispensing of dermatological agents, from 3.9 to 7.9 per 1000 women aged 15-49 years. LARC overlap was inferred for 2059 women at the time of first dispensing of category X medications (13.2%); 3441 had been dispensed any type of hormonal contraception (22.1%). The proportion with LARC overlap was smallest for those dispensed dermatological agents (1806 of 14 331 women, 12.6%); for this drug class, both LARC overlap (adjusted odds ratio [aOR], 0.17; 95% confidence interval [CI], 0.14-0.20) and any hormonal contraception overlap (aOR, 0.28; 95% CI, 0.25-0.32) were less likely for those aged 15-19 years than for women aged 25-29 years.

Conclusions: concurrent use of highly effective hormonal contraception at the time of first dispensing of category X medications is low in Australia, raising concerns about potential fetal harms during unintended pregnancies. Awareness of the importance of hormonal contraception and its uptake by women prescribed category X medications should be increased.

0025-729x
367-373
Grzeskowiak, Luke E.
18c429e9-118d-4609-a434-48a3d9bf086f
Moore, Vivienne
95ec0cb2-f419-4f50-b1fa-0534377a1051
Hall, Kelly
0920c133-5fcb-4371-9e5f-480bb18e2f77
Ilomäki, Jenni
712a85a2-48b1-4164-9a53-13cda9870efd
Schoenaker, Danielle
84b96b87-4070-45a5-9777-5a1e4e45e818
Lovegrove, Elizabeth
d7b61630-099a-4faf-94a8-10506cc9887c
Mazza, Danielle
766cf988-0c5a-4031-9a6a-66d2623715ce
Black, Kirsten I
92a2319f-a921-4016-b972-6e9ec1eb3a5f
Kennedy, Debra S.
ea2e6073-673c-4e0f-a319-ddf012dc4982
Davies, Michael J.
1b92a127-c616-4558-9c11-737294fced41
Rumbold, Alice
ee679ec9-80ea-4e37-a6eb-8fbfa9927d37
Grzeskowiak, Luke E.
18c429e9-118d-4609-a434-48a3d9bf086f
Moore, Vivienne
95ec0cb2-f419-4f50-b1fa-0534377a1051
Hall, Kelly
0920c133-5fcb-4371-9e5f-480bb18e2f77
Ilomäki, Jenni
712a85a2-48b1-4164-9a53-13cda9870efd
Schoenaker, Danielle
84b96b87-4070-45a5-9777-5a1e4e45e818
Lovegrove, Elizabeth
d7b61630-099a-4faf-94a8-10506cc9887c
Mazza, Danielle
766cf988-0c5a-4031-9a6a-66d2623715ce
Black, Kirsten I
92a2319f-a921-4016-b972-6e9ec1eb3a5f
Kennedy, Debra S.
ea2e6073-673c-4e0f-a319-ddf012dc4982
Davies, Michael J.
1b92a127-c616-4558-9c11-737294fced41
Rumbold, Alice
ee679ec9-80ea-4e37-a6eb-8fbfa9927d37

Grzeskowiak, Luke E., Moore, Vivienne, Hall, Kelly, Ilomäki, Jenni, Schoenaker, Danielle, Lovegrove, Elizabeth, Mazza, Danielle, Black, Kirsten I, Kennedy, Debra S., Davies, Michael J. and Rumbold, Alice (2024) Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013-2021: a retrospective cohort study. Medical Journal of Australia, 221 (7), 367-373. (doi:10.5694/mja2.52451).

Record type: Article

Abstract

Objectives: to examine patterns in the dispensing of category X medications (Therapeutic Goods Administration categorisation system for prescribing medicines in pregnancy) to women aged 15-49 years in Australia during 2008-2021, and patterns of concurrent use of hormonal long-acting reversible contraception (LARC) and other hormonal contraception.

Study design: retrospective cohort study; analysis of 10% random sample of national Pharmaceutical Benefits Scheme dispensing data.

Participants, Setting: women aged 15-49 years dispensed category X medications, Australia, 1 January 2013 - 31 December 2021.

Main outcome measures: incident and prevalent dispensing of category X medications, by medication class, age group, and year; contraceptive overlap (proportions of women dispensed hormonal LARC or other hormonal contraception that overlapped the first dispensing of category X medications), by medication class.

Results: among 15 627 women aged 15-49 years dispensed category X medications during 2013-2021, the prevalence of dispensing increased from 4.6 in 2013 to 8.7 per 1000 women aged 15-49 years in 2021; the largest increase was for the dispensing of dermatological agents, from 3.9 to 7.9 per 1000 women aged 15-49 years. LARC overlap was inferred for 2059 women at the time of first dispensing of category X medications (13.2%); 3441 had been dispensed any type of hormonal contraception (22.1%). The proportion with LARC overlap was smallest for those dispensed dermatological agents (1806 of 14 331 women, 12.6%); for this drug class, both LARC overlap (adjusted odds ratio [aOR], 0.17; 95% confidence interval [CI], 0.14-0.20) and any hormonal contraception overlap (aOR, 0.28; 95% CI, 0.25-0.32) were less likely for those aged 15-19 years than for women aged 25-29 years.

Conclusions: concurrent use of highly effective hormonal contraception at the time of first dispensing of category X medications is low in Australia, raising concerns about potential fetal harms during unintended pregnancies. Awareness of the importance of hormonal contraception and its uptake by women prescribed category X medications should be increased.

Text
Medical Journal of Australia - 2024 - Grzeskowiak - Concurrent use of hormonal long‐acting reversible contraception by - Version of Record
Available under License Creative Commons Attribution.
Download (673kB)

More information

e-pub ahead of print date: 16 September 2024
Published date: 7 October 2024

Identifiers

Local EPrints ID: 495077
URI: http://eprints.soton.ac.uk/id/eprint/495077
ISSN: 0025-729x
PURE UUID: cdaa8bdc-12ca-468e-a31b-aff710b80e60
ORCID for Danielle Schoenaker: ORCID iD orcid.org/0000-0002-7652-990X

Catalogue record

Date deposited: 28 Oct 2024 17:58
Last modified: 29 Oct 2024 03:00

Export record

Altmetrics

Contributors

Author: Luke E. Grzeskowiak
Author: Vivienne Moore
Author: Kelly Hall
Author: Jenni Ilomäki
Author: Danielle Mazza
Author: Kirsten I Black
Author: Debra S. Kennedy
Author: Michael J. Davies
Author: Alice Rumbold

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×